Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Credit If Credit’s Due

June 29, 2015 | A version of this story appeared in Volume 93, Issue 26

June 15, page 16: The Business Concentrate “Product Fragrances Divulged” should have indicated that SC Johnson has committed to reveal fragrance ingredients in its consumer products at levels down to 0.09%, not 0.9%.

The DuPont-Trian controversy had far more substance than you reported in your editorial (C&EN, May 25, page 5). You should reexamine two premises: first, that R&D performance is measured by R&D spending, and second, that long-term performance is independent from short-term performance.

Other venerable companies have had great R&D reputations but have been unable to adequately monetize R&D spending. Bell Labs, 3M, Merck & C0., and Pfizer come to mind. I think you recognize that DuPont’s migration to life sciences is a business activity where the DuPont know-how has been acquired rather than developed in-house at DuPont’s labs. DuPont has been on a long-term acquisition spree precisely because its labs haven’t delivered adequate results.

Poorly performing companies always complain that investors focus on short-term results when the companies in question have performed poorly in the short term. These same companies have been challenged because they have not only per-formed poorly short term but also performed poorly long term. A company performing well long term is invariably performing well also in the short term. You can’t succeed in the long term without also succeeding in the short term.

I praise Ellen Kullman for substantially improving DuPont’s long-term performance. Whether that success has been adequate remains a fair question.

Tony Pavone
Half Moon Bay, Calif.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.